Literature DB >> 6185128

Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung.

N Saijo, E Shimizu, M Shibuya, N Irimajiri, T Takizawa, K Eguchi, T Shinkai, K Tominaga, Z Shimabukuro, T Taniguchi, A Hoshi.   

Abstract

The effect of chemotherapy on natural killer (NK) activity and antibody-dependent cell-mediated cytotoxicity (ADCC) in 15 advanced carcinomas of the lung was examined with regard to the drug, dose, route and timing of administration. The relationship between the effect of chemotherapy on the prognosis for the patients, and the changes in NK activity and ADCC, was also analysed. The NK activity and ADCC in patients with poor prognosis were significantly subnormal, even before treatment. The NK activity and ADCC began to decrease 2 weeks after the initiation of treatment and reached the lowest level during the 3rd or 4th week in all patients. Thereafter, they returned to the pretreatment level in 8 patients with stabilized disease. In contrast, they were not restored in 7 patients with progressive disease and poor prognosis. In 4 patients it was found that the effect of chemotherapy with pepleomycin and carbazilquinone on NK activity and ADCC differed according to the drug used. From this pilot study it is suggested that NK activity and ADCC are valuable prognostic factors in patients with advanced carcinoma of the lung, and that detailed analysis of the effect of each anticancer agent on NK activity and ADCC is desirable for the establishment of better treatment regimens for advanced carcinoma of the lung.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6185128      PMCID: PMC2011091          DOI: 10.1038/bjc.1982.182

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

Review 1.  Natural killer cells as antitumor effector cells.

Authors:  R B Herberman; H T Holden
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

2.  The glomerular permeability determined by dextran clearance using Sephadex gel filtration.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1968       Impact factor: 1.713

3.  Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice.

Authors:  A Mantovani; W Luini; G Peri; A Vecchi; F Spreafico
Journal:  J Natl Cancer Inst       Date:  1978-11       Impact factor: 13.506

4.  Lymphocyte mediated natural cytotoxicity in neoplasia.

Authors:  M Menon; S S Stefani
Journal:  Oncology       Date:  1978       Impact factor: 2.935

5.  Rebound phenomenon of phytohemagglutinin skin reactivity in leukemia and malignant lymphoma after chemotherapy.

Authors:  S Sone; K Yata; E Tsubura
Journal:  Gan       Date:  1977-08

6.  Effect of operation and radiotherapy on antibody-dependent cellular cytotoxicity.

Authors:  J A McCredie; H R MacDonald; S B Wood
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

7.  Spontaneous human lymphocyte-mediated cytotoxicity againts tumour target cells. I. The effect of malignant disease.

Authors:  H F Pross; M G Baines
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

8.  Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease.

Authors:  O Eremin; J Ashby; J P Stephens
Journal:  Int J Cancer       Date:  1978-01-15       Impact factor: 7.396

9.  Effects of adriamycin on the activity of mouse natural killer cells.

Authors:  A Santoni; C Riccardi; V Sorci; R B Herberman
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

10.  Enhancement of human natural cell-mediated cytotoxicity by interferon.

Authors:  M Moore; M R Potter
Journal:  Br J Cancer       Date:  1980-03       Impact factor: 7.640

View more
  10 in total

1.  Effect of chemotherapy on NK function in the peripheral blood of cancer patients.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

Authors:  N Saijo; A Ozaki; H Nakano; M Sakurai; H Takahashi; Y Sasaki; A Hoshi
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

3.  Effect on natural killer and antibody-dependent cellular cytotoxicity of adjuvant cytotoxic chemotherapy including melphalan in breast cancer.

Authors:  I R Mackay; M D Goodyear; C Riglar; J Penschow
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 4.  Can cancer chemotherapy enhance the malignant behaviour of tumours?

Authors:  T J McMillan; I R Hart
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents.

Authors:  N Saijo; A Ozaki; Y Beppu; K Takahashi; J Fujita; Y Sasaki; H Nomori; M Kimata; E Shimizu; A Hoshi
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

6.  Enhanced K-cell activity in the peripheral blood of patients with malignant disease.

Authors:  T Bakács; P Czanik; I Kimber; G Ringwald; M Moore; E Abrahám
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Prognostic value of non-MHC-restricted killer cell activity in lung cancer.

Authors:  A M Malygin; A A Redjko; O N Pogodina; N A Karaseva; Y F Koval; T Timonen
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Suppression of natural killer activity in patients treated with cisplatin and methylprednisolone.

Authors:  K Takahashi; N Saijo; M Kimata; Y Sasaki; J Fujita; H Futami; E Shimizu; K Eguchi; T Shinkai; K Tominaga
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

9.  The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.

Authors:  John T Patton; Mark E Lustberg; Gerard Lozanski; Sabrina L Garman; William H Towns; Callie M Drohan; Amy Lehman; Xiaoli Zhang; Brad Bolon; Li Pan; A Douglas Kinghorn; Michael R Grever; David M Lucas; Robert A Baiocchi
Journal:  Oncotarget       Date:  2015-02-20

10.  Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?

Authors:  Kendel Quirk; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Front Pharmacol       Date:  2017-10-17       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.